Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.2293 USD
−284.23 M USD
147.75 M USD
93.78 M
About FibroGen, Inc
Sector
CEO
Thane Wettig
Headquarters
San Francisco
Website
Founded
1993
FIGI
BBG000FW5ZL6
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of FGEN is 0.3954 USD — it has increased by 2.12% in the past 24 hours. Watch FibroGen, Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange FibroGen, Inc stocks are traded under the ticker FGEN.
FGEN stock has risen by 6.52% compared to the previous week, the month change is a 14.48% rise, over the last year FibroGen, Inc has showed a −19.47% decrease.
FGEN reached its all-time high on Jul 9, 2018 with the price of 68.5500 USD, and its all-time low was 0.1800 USD and was reached on Nov 13, 2024. View more price dynamics on FGEN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
FGEN stock is 6.12% volatile and has beta coefficient of 3.65. Track FibroGen, Inc stock price on the chart and check out the list of the most volatile stocks — is FibroGen, Inc there?
Today FibroGen, Inc has the market capitalization of 39.84 M, it has increased by 15.69% over the last week.
Yes, you can track FibroGen, Inc financials in yearly and quarterly reports right on TradingView.
FibroGen, Inc is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
FGEN earnings for the last quarter are −0.17 USD per share, whereas the estimation was −0.31 USD resulting in a 44.50% surprise. The estimated earnings for the next quarter are −0.22 USD per share. See more details about FibroGen, Inc earnings.
FibroGen, Inc revenue for the last quarter amounts to 46.33 M USD, despite the estimated figure of 34.84 M USD. In the next quarter, revenue is expected to reach 20.23 M USD.
FGEN net income for the last quarter is −17.08 M USD, while the quarter before that showed −15.54 M USD of net income which accounts for −9.91% change. Track more FibroGen, Inc financial stats to get the full picture.
No, FGEN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 23, 2024, the company has 486.00 employees. See our rating of the largest employees — is FibroGen, Inc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. FibroGen, Inc EBITDA is −90.19 M USD, and current EBITDA margin is −175.48%. See more stats in FibroGen, Inc financial statements.
Like other stocks, FGEN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade FibroGen, Inc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So FibroGen, Inc technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating FibroGen, Inc stock shows the sell signal. See more of FibroGen, Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.